PAX9 is a transcription factor of the PAX family characterized by a DNA-binding paired domain. Previous studies have suggested a potential role of PAX9 in squamous cell differentiation and carcinogenesis of the oro-oesophageal epithelium. However, its functional roles in differentiation and carcinogenesis remain unclear. In this study, Pax9 deficiency in mouse oesophagus promoted cell proliferation, delayed cell differentiation, and altered the global gene expression profile. Ethanol exposure downregulated PAX9 expression in human oesophageal epithelial cells in vitro and mouse forestomach and tongue in vivo. We further showed that PAX9 was downregulated in human oro-oesophageal squamous cell carcinoma (OESCC), and its downregulation was associated with alcohol drinking and promoter hypermethylation. Moreover, ad libitum feeding with a liquid diet containing ethanol for 40 weeks or Pax9 deficiency promoted N-nitrosomethylbenzylamine-induced squamous cell carcinogenesis in mouse tongue, oesophagus, and forestomach. In conclusion, PAX9 regulates squamous cell differentiation in the oro-oesophageal epithelium. Alcohol drinking and promoter hypermethylation are associated with PAX9 silencing in human OESCC. PAX9 downregulation may contribute to alcohol-associated oro-oesophageal squamous cell carcinogenesis.
Introduction
PAX9 is a transcription factor (TF) of the PAX family characterized by a DNA-binding paired domain. Being expressed in somites, pharyngeal pouches, and mesenchyme, PAX9 is essential for the development of the thymus, parathyroid, limbs, palate and teeth during mouse embryogenesis. Homozygous Pax9 knockout mice die shortly after birth, owing to cleft palate [1] . Subsequent studies have also clearly demonstrated an essential role of PAX9 in the development of filiform papillae and taste buds of the tongue, lips, and intervertebral discs [2] [3] [4] [5] . However, in adults, PAX9 expression is restricted to the endocrine tissues (e.g. thymus and parathyroid) and the upper gastrointestinal tract (e.g. tongue, oesophagus, salivary gland, and cheek epithelium), with the strongest expression being in the tongue [6] .
Previous studies have suggested a potential role for the absence of PAX9 in human oesophageal squamous cell carcinoma (ESCC) and oral squamous cell carcinoma (OSCC). In human ESCC tissue samples, PAX9 was found to be lost or downregulated, and progressive loss of PAX9 expression was correlated with increasing malignancy [7] . PAX9 expression was associated with better survival and radiosensitivity [8] . In human OSCC cells, PAX9 expression was essential for cell growth and survival [9] . In Barrett's oesophagus, a human disease PAX9 and oro-oesophageal squamous cell carcinoma 165 characterized by intestinal metaplasia of oesophageal squamous epithelium, PAX9 was found to be downregulated [10] , suggesting its involvement in squamous differentiation. Pax9 and its downstream genes were involved in the terminal maturation of oesophageal epithelium of mouse oesophagus [11] . Moreover, morpholino knockdown of pax9 in zebrafish resulted in loss or disorganization of squamous epithelium in the tongue [12] . These findings support the hypothesis that PAX9 may regulate squamous epithelial cell differentiation in adult oro-oesophageal epithelium.
In this study, we aimed to determine the functional role of PAX9 in oro-oesophageal epithelium by using tissue-specific PAX9-deficient mice, and human cells and tissues.
Materials and methods

Human tissue samples
Human ESCC and OSCC tissue samples were obtained from Duke University Medical Center and Beijing Stomatological Hospital, respectively, with informed written consent and institutional IRB approval (Pro39682 and Pro56638). All human samples (n = 26) were coded with patient identifiers removed. Clinical data, including alcohol exposure, were collected from the medical record. Patients with a self-reported history of alcohol drinking (n = 15) were regarded as 'drinkers' (five drinks per week on average), and those who reported never drinking alcohol (n = 5) were regarded as 'non-drinkers'. Occasional drinkers (n = 6) were excluded from further analysis of the association between alcohol drinking and PAX9 expression. A human ESCC tissue array with tumours and matched normal adjacent tissues (Cat no.: HEso-Squ060PG-01) and a human OSCC array with tumours and non-matched normal tissues (Cat no.: OR601b) were purchased from US Biomax (Derwood, MD, USA).
Cell culture and treatments
Human ESCC cells, i.e. KYSE510, KYSE450, and KYSE70, were obtained from the ATCC (Manassas, VA, USA) and the ECACC (Porton Down, Salisbury, UK) with proper authentication. KYSE510 and KYSE450 cells were exposed to ethanol. KYSE70 cells were treated with 5-aza-2 ′ -deoxycytidine (DAC) (Sigma-Aldrich, St Louis, MO, USA) for 72 h.
Animal experiments
All animal experiments were approved by the IACUC at the North Carolina Central University. Krt5Cre mice [13] and Pax9 loxP/loxP mice [14] were crossed to generate tissue-specific Pax9-deficient mice (Krt5Cre;Pax9 loxP/loxP ). Tissue samples (tongue, oesophagus, and forestomach) were harvested for analysis of morphology and gene expression, and transmission electron microscopy (TEM).
In an ethanol exposure study, wild-type C57BL/6 J mice (Jackson Laboratory, Bar Harbor, ME, USA) were given water ad libitum, or 20% ethanol (plus 0.3% saccharin) in the drink for 4 weeks, or 15% ethanol (plus 0.3% saccharin) in the drink for 40 weeks.
In a carcinogenesis study, N-nitrosomethylbenzylamine (NMBA) was used to induce tumourigenesis in mouse oesophagus and forestomach [15] . Mice were given six intragastric doses of NMBA (Ash Stevens, Riverview, MI, USA) at 2 mg/kg body weight twice weekly for 3 weeks. Wild-type C57BL/6 J mice were given the Lieber-DeCarli Regular Control diet (710027; Dyets, Bethlehem, PA, USA) (group A), or an isocaloric Lieber-DeCarli diet plus 6.4% v/v ethanol (710260; Dyets) (group B) ad libitum. The Lieber-DeCarli diet is a high-fat, nutritionally complete liquid diet, and was designed to partially overcome the murine dislike of ethanol [16] . Pax9-deficient mice were given the control liquid diet (group C) ( Table 1 ). All mice were killed at 40 weeks and analysed for tumourigenesis in the tongue, oesophagus, and forestomach. The numbers of macroscopically visible tumours (≥0.5 mm in diameter) in mouse forestomach and tongue were scored. Tissues were processed routinely for paraffin sectioning (5 μm), haematoxylin and eosin (H&E) staining, and histopathology. Microscopic lesions including dysplasia, papilloma, and squamous cell carcinoma (SCC), were diagnosed according to established criteria [15] .
Western blotting
Protein was isolated from the human ESCC cells and mouse tissues with a standard method. In brief, tissue lysates were prepared by homogenizing tissue with the TissueLyser bead mill (Qiagen, Valencia, CA, USA) in RIPA buffer (Sigma-Aldrich). Cell debris was removed by a short centrifugation, and an aliquot of cleared lysate was kept for protein quantification with the BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Proteins were detected with a rabbit monoclonal anti-PAX9 antibody (1: We performed immunofluorescence double staining for BrdU and Ki67 to test whether the BrdU-positive cells that were retained in the epithelial layer were still proliferating 5 days after pulse-labelling (50 mg/kg, intraperitoneal) [17] . Immunofluorescence double staining was conducted on the basis of standard procedures. Ki67 and BrdU were detected with a rabbit anti-Ki67 antibody (1:200, RM-9106; Thermo Scientific) and a rat monoclonal anti-BrdU antibody (1:1000, ab6326; Abcam) overnight at 4 ∘ C, and then with a goat anti-rabbit Alexa 568 antibody and a goat anti-rat Alexa 488 antibody (1:1000, A-11008 and A-11077; Thermo Scientific).
Transmission electron microscopy
Mouse tissue was fixed with 4% glutaraldehyde in cacodylate buffer for at least 1 h. Thick and thin sections were prepared on a Reichert-Jung ultramicrotome (Leica, Bannockburn, IL, USA). Thick sections were stained with 1% toluidine blue-borax for selection with light microscopy of the appropriate areas for thin sections. Thin sections were prepared, mounted on copper grids, and double stained for examination under a Philips CM 12 electron microscope (FEI, Hillsboro, OR, USA).
Gene microarray analysis
For gene microarray analysis, total RNA was extracted from mouse forestomach or mouse oesophageal epithelium with an RNeasy Fibrous Tissue Mini Kit (Qiagen), according to the manufacturer's instructions. Microarray experiments were performed with Agilent mouse 4x44k microarrays. The raw data have been submitted to the NCBI GEO database (series GSE75373 and GSE96735). As previously described [11] , differentially expressed genes were obtained from two-class significance analysis of microarrays (SAM) in Excel with the median number of false positives being <1. Gene set analysis (GSA) was carried out as an add-in in Excel with curated gene sets in three major categories: canonical pathway, gene ontology, and TF. Knowledge-based gene sets were generated on the basis of the literature, and have been successfully used in our previous microarray study [11] . The Pax9 gene set was based on a list of genes that are differentially expressed in Pax9 knockout mice [2] . Hierarchical clustering analysis and principal component analysis (PCA) were performed with the R package. Microarray data of four GEO datasets (GSE23400, GSE20347, GSE13601, and GSE6631) were downloaded and analysed to compare PAX9 mRNA expression in cancer and in matched normal tissue.
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The methylation status of each CpG site in the promoter regions (supplementary material, Figure S7 ) was determined individually as an artificial C/T singlenucleotide polymorphism with QCpG software (Qiagen). A series of unmethylated and methylated DNAs were included as controls in each polymerase chain reaction (PCR).
Reverse Transcription PCR (RT-PCR), Reverse Transcription quantitative PCR (RT-qPCR) and chromatin immunoprecipitation (ChIP)
For regular RT-PCR, total RNA was reverse transcribed with the Advantage RT-for-PCR kit (Clontech Laboratories, Mountain View, CA, USA), according to the manufacturer's instructions. Pax9 exon 2 was detected with the following primer pairs (predicted size: 278 bp):
. Quantitative PCR was performed on cDNA pools to assess the expression levels of genes of interest with primers and probes obtained from Applied Biosystems (Foster City, CA, USA), by the use of TaqMan and 96-well optical plates, with an ABI 7900HT Fast Real-Time PCR system in triplicate.
PAX9-binding sites within the 5 ′ -upstream DNA sequence of Krt35 (ENSMUSG00000048013) were predicted by Anchored Combination TFBS Cluster Analysis (oPOSSUM version 3.0). ChIP analysis was performed in triplicate with an EZ-ChIP kit (Millipore, Billerica, MA, USA), according to the manufacturer's instructions, with the above-mentioned anti-PAX9 antibody. Immunoprecipitated DNA or input was PCRamplified with the following primer pairs: Krt35 (5 ′ -CCACATCCTGAGTTCAATCC-3 ′ and 5 ′ -CCAA GACAGGATCTCTCATTAC-3 ′ ; predicted size 174 bp); and negative control P63 (5 ′ -CAAATGTTGCTTGTCT GGTG-3 ′ and 5 ′ -GTCAGTCGAGTGCACAGTTT-3 ′ ; predicted size 210 bp).
Statistical analyses
GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA) was used for Student's t-test, Fisher's exact test, and McNemar's test, with the statistical significance level set at 0.05. All comparisons were two-sided. Figure  S1A ) and IHC staining (supplementary material, Figure  S1B -E). IHC assessment for PCNA showed epithelial hyperproliferation in Pax9-deficient oesophagus (supplementary material, Figure S1F -H). Papilloma-like structures were formed in the squamous epithelium of Pax9-deficient oesophagus ( Figure 1B, D) as compared with control oesophagus ( Figure 1A, C) . Hyperproliferation was evident with an increased number of BrdU-positive cells ( Figure 1E-H) . Apoptosis as detected with a TUNEL assay was slightly different between Pax9-deficient oesophagus (0.7 ± 0.4%; Figure 1J ) and control oesophagus (0.2 ± 0.1%; Figure 1I ). Toluidine blue staining showed increased numbers of keratohyalin granules in the keratinized cells and palisading of basal cells in mutant oesophagus (Figure 1K, L) . TEM showed that the basal layer of mutant oesophagus, the intercellular space, desmosomes and adhesion fingers between cells were disorganized ( Figure 1M, N) . On the fifth day following a BrdU pulse injection, some suprabasal cells of mutant oesophagus remained strongly positive for BrdU and Ki67 ( Figure 1P , R, T, V; yellow arrows) as compared with control oesophagus ( Figure 1O , Q, S, U), suggesting that migration of these cells towards the lumen was impaired.
Results
Oesophageal phenotypes of
Gene microarray analysis showed that, in Pax9-deficient mice, 60 genes were downregulated, of which some were associated with squamous cell differentiation (e.g. Krtap3-3, Krt1-24/Krt35, and Sfrp5), and 83 genes were upregulated (e.g. Wnt3, Foxa3, and Gata3) (Figure 2A ). Multiple gene sets were enriched in control oesophagus, including 'Pax9 target genes'. Several gene sets were enriched in Pax9-deficient oesophagus, e.g. 'basal layer', 'Sox2 target genes', and 'cell-cell junction' (supplementary material, Table S1 ). qRT-PCR showed upregulation of hedgehog pathway genes (Gli1 and Gli2), Wnt pathway genes (Wnt3 and Gata3), and genes highly expressed in basal cells (Sox2 and P63), and downregulation of Pax9 and its downstream genes (Krt35) (supplementary material, Figure S2A ). ChIP-PCR confirmed PAX9 binding to the 5 ′ upstream DNA sequence of Krt35 (supplementary material, Figure S2B ). IHC staining for the protein products of the selected genes involved in epithelial differentiation showed upregulation of SOX2 ( Figure 2B (GSE23400, GSE20347, GSE13601, and GSE6631), and these showed significant downregulation of PAX9 mRNA in human ESCCs (supplementary material, Figure S3A , B) and human OSCCs (supplementary material, Figure S3C , D), as compared with matched normal tissues. Using two commercially available tissue microarrays, we obtained positive PAX9 staining in two of 29 ESCCs and 25 of 29 matched normal oesophageal tissues (P < 0.0001), and in six of 50 OSCCs and six of 10 normal oral mucosal tissues (P = 0.0026).
In our human samples, IHC analysis showed a dramatic decrease in PAX9 expression in ESCCs versus adjacent normal oesophageal tissues ( Figure 3C , D, E). Histopathology of ESCCs and adjacent normal oesophageal tissues was confirmed by H&E staining (Figure 3A, B) . Interestingly, a significant decrease in the number of PAX9-positive cells was observed in normal tissue from drinkers as compared with normal tissue from non-drinkers ( Figure 3F ). Even in cancer tissues, a slight decrease in PAX9 expression was also observed in tissue from drinkers as compared with tissue from non-drinkers. Thirty-two genes were downregulated by exposure to 20% ethanol for 4 weeks, and 581 genes were upregulated and 1506 genes were downregulated by exposure to 15% ethanol for 40 weeks, as compared with controls (supplementary material, Table S2 ). Using GSA analysis, we found enrichment of multiple gene sets, including 'Pax9 target genes' and 'epidermal differentiation complex' in control forestomach, suggesting downregulation of Pax9 target genes by ethanol exposure ( Figure 4H ). PCA analysis and clustering analysis also supported distinct gene expression profiles of three groups (supplementary material, Figure S5 ).
Ethanol downregulates PAX9 expression in oro-oesophageal squamous epithelial cells in vitro and in vivo
IHC staining showed reduced expression of loricrin (a marker of squamous cell differentiation) in ethanol-exposed forestomach as compared with control ( Figure 4I-K) , indicating that squamous differentiation was suppressed by ethanol. Downregulation of PAX9 expression in mouse forestomach was also observed ( Figure 4L-N) , especially in those exposed to 15% ethanol for 40 weeks. Pax9 downregulation was further confirmed by western blotting and qRT-PCR (Figure 4O-Q) . In addition to forestomach, ethanol-exposed mouse tongue also expressed PAX9 at a reduced level, as shown by western blotting and IHC staining (supplementary material, Figure S6 ). No obvious change in PAX9 expression was observed in mouse oesophagus (data not shown). 
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Promoter hypermethylation is associated with PAX9 silencing in human ESCC cells and OSCC tissues
To understand the molecular mechanism through which alcohol drinking downregulates PAX9 expression, CpG sites in the promoter regions of two different PAX9 transcriptional start sites (supplementary material, Figure S7 ) were pyrosequenced in control and DAC-treated KYSE70 cells. Consistent with an increase in PAX9 expression (Figure 5A ), the methylation level of DAC-treated KYSE70 cells was lower than that of control ( Figure 5B ). More importantly, the methylation levels of both transcripts were higher in OSCC tissues than in matched normal tissues ( Figure 5C ).
We then pyrosequenced the promoter regions of two different PAX9 transcriptional start sites in ethanol-exposed KYSE510 cells (100 mM for 72 h) and mouse forestomach (15% for 40 weeks). Despite the decrease in PAX9 expression, no significant difference in methylation levels was found between control samples and ethanol-exposed samples (supplementary material, Figure S8 ).
Increased susceptibility to NMBA-induced oro-oesophageal squamous cell carcinogenesis in Krt5Cre;Pax9 loxP/loxP mice
To determine whether Pax9 deficiency promotes oro-oesophageal squamous cell carcinoma (OESCC), wild-type or Pax9-deficient mice were given six intragastric doses of NMBA and killed at 40 weeks. The number of macroscopically visible tumours in mouse forestomach was significantly increased in Pax9-deficient mice as compared with control ( Figure 6A ). Seven Pax9-deficient mice developed tongue tumours. Similarly what was seen in Pax9-deficient mice, an isocaloric Lieber-DeCarli diet containing ethanol for 40 weeks significantly enhanced forestomach tumourigenesis in wild-type mice as compared with a control liquid diet. Under the microscope, the incidence of oesophageal papilloma was significantly increased in ethanol-exposed mice as compared with control. Incidence rates of forestomach dysplasia and SCC significantly increased, from 22.2% and 5.6%, respectively, in control mice to 81.8% and 31.8%, respectively, in Pax9-deficient mice. The incidence of tongue lesions (dysplasia, papilloma, and SCC) was also significantly increased, from 0% in control mice to 36.4% in Pax9-deficient mice (Table 1; Figure 6B-I) . IHC staining showed that PAX9 expression was not dra172 Z Xiong et al Figure 5 . PAX9 promoter hypermethylation in KYSE70 cells and human OSCC samples. KYSE70 cells treated with different concentrations of DAC were analysed by western blotting for PAX9 expression (A). The percentages of methylation at CpG sites in the promoter regions of two different PAX9 transcriptional start sites (TSSs) were analysed by pyrosequencing for comparison between control and DAC-treated KYSE70 cells (B) (n = 3; *P < 0.05). The percentages of methylation at CpG sites in the promoter regions of two different PAX9 transcriptional start sites were analysed by pyrosequencing for comparison between human OSCC and matched normal samples (C) (n = 6; *P < 0.05). P values were determined with Student's t-test.
decreasing expression from histologically normal to dysplasia and cancer (supplementary material, Figure  S9B-D) .
Discussion
This study is the first to demonstrate functional roles of PAX9 in the adult oro-oesophageal epithelium. Tissue-specific Pax9 deficiency was associated with squamous epithelial cell hyperproliferation, delayed cell differentiation and an altered global gene expression profile in mouse oesophagus. PAX9 downregulation was confirmed in human OESCC, and was associated with alcohol drinking. Ethanol exposure downregulated PAX9 expression in oro-oesophageal squamous epithelial cells in vitro and in vivo. Promoter hypermethylation was found to be associated with PAX9 silencing in human OESCC. Furthermore, both Pax9 deficiency and ethanol exposure promoted OESCC in vivo.
As a transcription factor, PAX9 is expressed in adult squamous epithelial cells in the upper gastrointestinal tract, with the strongest expression in the tongue [6] . Clinically, PAX9 mutations have been reported in patients with oligodontia and cleft palate [18, 19] . Previous studies by us and others have suggested a potential role of PAX9 in squamous cell differentiation and carcinogenesis [7, [9] [10] [11] [12] . In this study, Pax9 deficiency enhanced epithelial cell proliferation (papilloma-like structure, and increases in the BrdU-labelling index and PCNA expression) and inhibited cell differentiation (loricrin downregulation and delayed maturation of BrdU-labelled cells) in mouse oesophagus (Figures 1  and 2 ).
Using GEO datasets and our own tissue samples, we further confirmed PAX9 downregulation in human ESCC and OSCC (supplementary material, Figure S3 ; Figure 3 ). Although human ESCC with a low level of PAX9 expression does have similarities in gene expression to Pax9-deficient oesophagus (data not shown), it should be noted that mouse array and human array did not test the same genes, particularly in the early days. Therefore, this finding should be treated with caution. An interesting association between PAX9 downregulation and alcohol drinking in human ESCC led us to investigate whether alcohol drinking, which is a major risk factor for OESCC [20] [21] [22] , may cause PAX9 downregulation. In fact, OSCC has a stronger association with alcohol exposure than cancers of any other organ sites [23] [24] [25] . A case-control study on the risk of ESCC showed a higher odds ratio (OR) for heavy drinkers (OR = 10) than for tobacco smokers (OR = 5.8). Heavy drinking led to increased numbers of SCC and dysplastic lesions in human oesophagus [26, 27] . Acetaldehyde, an ethanol metabolite, is believed to be a carcinogen that contributes to the development of ESCC. Genetic polymorphisms of genes involved in ethanol metabolism, such as those encoding acetaldehyde dehydrogenase and alcohol dehydrogenase, are also strongly and consistently associated with OESCC [21, 22] . Our data showed that ethanol exposure caused a time-dependent and dose-dependent decrease in PAX9 expression in oesophageal epithelial cells in vitro (supplementary material, Figure  S4 ). More importantly, ethanol exposure reduced PAX9 expression in mouse forestomach ( Figure 4 ) and tongue (supplementary material, Figure S6 ). The lack of a significant effect of ethanol exposure on PAX9 expression in mouse oesophagus was unexpected. Presumably, the short duration of contact may account for the relatively weak effect of ethanol on oesophageal epithelium.
We next aimed to understand the molecular mechanism leading to PAX9 silencing in OESCC. PAX9 has been identified as a gene that is subject to promoter methylation in human ESCC and in lung cancer [28, 29] . A genome-wide DNA methylome analysis revealed widespread ethanol-induced alterations, with significant hypermethylation of many regions of chromosomes in human embryonic stem cells [30] . We therefore pyrosequenced the promoter regions of two different PAX9 transcriptional start sites (supplementary material, Figure S7 ). Consistent with our hypothesis, the methylation percentages of multiple CpG sites in OSCC samples were significantly higher than those in matched normal tissues ( Figure 5C ). A demethylating 174 Z Xiong et al agent increased PAX9 expression in KYSE70 cells, and also reduced CpG methylation percentages ( Figure 5A , B). However, ethanol exposure of KYSE510 cells or mouse forestomach did not result in PAX9 promoter hypermethylation, even though PAX9 expression was downregulated (supplementary material, Figure S8 ). Our data suggested that alternative mechanisms are responsible for PAX9 downregulation by ethanol in our experimental settings. However, we cannot exclude the possibility that our experimental settings, i.e. ethanol exposure of cells and feeding mice with ethanol, may not exactly reproduce the sequential changes leading to PAX9 silencing in human OESCC. It remains unknown whether promoter hypermethylation may be associated with PAX9 downregulation due to alcohol drinking.
Our last question was whether Pax9 deficiency contributes to OESCC in vivo. In Pax9-deficient mice, we observed significant increases in the number of forestomach tumours and the incidence rates of oesophageal and forestomach lesions (papilloma, dysplasia, and SCC) (Table 1; Figure 6 ). Because NMBA is not expected to induce tumours in the tongue of wild-type mice [15] , development of tongue lesions in Pax9-deficient mice further supported the importance of PAX9 downregulation in the development of OESCC. Consistent with the association between alcohol drinking and PAX9 downregulation, feeding mice with an isocaloric liquid diet containing ethanol significantly increased the number of forestomach papilloma and the incidence of oesophageal papilloma ( Figure 6A ; Table 1 ). On the basis of the gene expression data, we speculate that PAX9 downregulation may allow activation of multiple oncogenic pathways, and thus facilitate the development of OESCC. For example, Shh signalling activation results in the expansion of the epithelial precursor cell compartment [17] . It is of note that hedgehog ligand is required for the growth of digestive tract tumours, including oesophageal cancer [31] . Wnt signalling is involved in the early differentiation of oesophageal epithelium [11] . In OESCC, poor histological differentiation and clinical outcome are associated with increased expression of nuclear β-catenin [32] . Exposure to carcinogens and ethanol increases the overall β-catenin level in the tongue [33] . Sox2 and P63 are colocalized at genetic loci and co-regulate gene expression to facilitate the development of ESCC [34] . Transgenic overexpression of SOX2 itself was found to induce SCC in mouse forestomach [35] and lung [36] . It should be noted that humans do not have a forestomach. Therefore, enhanced forestomach carcinogenesis resulting from Pax9 deficiency may or may not be relevant to human ESCC.
Taken together, these findings show that PAX9 regulates squamous cell differentiation and carcinogenesis in oro-oesophageal epithelium. Our data support a novel mechanism whereby PAX9 downregulation may also contribute to alcohol-associated OESCC. Further studies are warranted to understand the upstream events leading to PAX9 downregulation by ethanol, and the downstream mechanisms that promote OESCC. Table S1 . Differentially expressed genes and enriched gene sets in Pax9-deficient esophagus as compared with control esophagus Table S2 . Differentially expressed genes and enriched gene sets in mouse forestomach due to alcohol drinking (20% in the drink for 4 weeks or 15% in the drink for 40 weeks)
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